The Biden administration will “temporarily” lift a policy put in place under the Trump administration that requires women seeking the abortion drug Mifepristone — also known as RU486 — to do so in person from a health professional. Lifting the policy will allow the pills to be distributed via mail.
FDA Commissioner Janet Woodcock told the American College of Obstetrics and Gynecologists that the FDA will allow healthcare providers in certain states to “exercise enforcement discretion.” Woodcock cited studies that dismissed any “serious safety concerns … occurring with medical abortion as a result of modifying the in-person dispensing requirement during the COVID-19 pandemic.”
March for Life, a pro-life organization, said of the policy change:
“With this action, the Biden administration has made it clear that it will prioritize abortion over women’s safety. Allowing unsupervised chemical abortions via telemedicine, without requiring timely access to medical care, will put women in grave danger.”
“Data released in 2018 by the FDA shows thousands of adverse events caused by abortion pills, including 768 hospitalizations and 24 deaths since 2000. Chemical abortions should have more medical oversight not less.”
CBS reported that the Biden administration’s “temporary” action handed “abortion-rights groups one of their first major victories of the new administration.”
The Department of Health and Human Services also proposed a rule change that would reverse a one of the Trump administration’s policies that prohibits the federal funding of abortion referral services.
Planned Parenthood, the nation’s largest abortion provider, was hit the hardest when Trump implemented that policy.
For decades, Biden — a lifelong Catholic — supported the 1980 Hyde Amendment, which prohibited taxpayer dollars from funding abortions. However, he reversed his stance when he ran on the Democratic ticket in 2020.